Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Cannot have received: systemic chemotherapy

Exception: neoadjuvant/adjuvant/chemoradiation for nonmetastatic NSCLC allowed if completed ≥12 months before diagnosis of metastatic NSCLC

Received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC. Note: Prior treatment with chemotherapy and/or radiation as a part of neoadjuvant or adjuvant therapy or chemoradiation therapy for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC

Cannot have received: anti-PD-1 therapy

Exception: prior anti-PD-1 or anti-PD-L1 for nonmetastatic NSCLC allowed if completed ≥12 months before diagnosis of metastatic NSCLC

Received prior therapy with an anti-programmed cell death 1 protein (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti programmed cell death ligand 2 (PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T lymphocyte-associated protein 4, OX-40, CD137). Note: Prior treatment with an anti-PD-1 or anti-PD-L1 agent for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC

Cannot have received: TROP2-targeted antibody-drug conjugate

Received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)-targeted antidrug conjugate (ADC)

Cannot have received: topoisomerase I inhibitor-containing antibody-drug conjugate

Received prior treatment with a topoisomerase I inhibitor-containing ADC